速递｜超8亿美元交易达成！诺和诺德布局非GLP-1减重药物

GLP1减重宝典2025-06-13

整理 | GLP1减重宝典内容团队诺和诺德正进一步巩固其在快速增长的肥胖治疗市场中的领先地位，近日宣布与Deep Apple Therapeutics达成一项最高价值达8.12亿美元的合作协议，获取针对非促胰素类GPCR靶点的小分子药物。这一战略合作是该公司一系列研发投资中的最新动作，旨在锁定下一代代谢疾病疗法。Deep Apple Therapeutics由投资机构Apple Tree ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2543578562?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-13 10:40","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2543578562","market":"us","top_or_hot":-1,"title":"速递｜超8亿美元交易达成！诺和诺德布局非GLP-1减重药物","media":"GLP1减重宝典","content":"<div>\n<p>整理 | GLP1减重宝典内容团队诺和诺德正进一步巩固其在快速增长的肥胖治疗市场中的领先地位，近日宣布与Deep Apple Therapeutics达成一项最高价值达8.12亿美元的合作协议，获取针对非促胰素类GPCR靶点的小分子药物。这一战略合作是该公司一系列研发投资中的最新动作，旨在锁定下一代代谢疾病疗法。Deep Apple Therapeutics由投资机构Apple Tree ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613104154a4a66191&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>速递｜超8亿美元交易达成！诺和诺德布局非GLP-1减重药物</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n速递｜超8亿美元交易达成！诺和诺德布局非GLP-1减重药物\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-13 10:40 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613104154a4a66191&s=b><strong>GLP1减重宝典</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>整理 | GLP1减重宝典内容团队诺和诺德正进一步巩固其在快速增长的肥胖治疗市场中的领先地位，近日宣布与Deep Apple Therapeutics达成一项最高价值达8.12亿美元的合作协议，获取针对非促胰素类GPCR靶点的小分子药物。这一战略合作是该公司一系列研发投资中的最新动作，旨在锁定下一代代谢疾病疗法。Deep Apple Therapeutics由投资机构Apple Tree ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613104154a4a66191&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613104154a4a66191&s=b","article_id":"2543578562","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613104154a4a66191&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2543578562","pubTimestamp":1749782430,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"整理 | GLP1减重宝典内容团队诺和诺德正进一步巩固其在快速增长的肥胖治疗市场中的领先地位，近日宣布与Deep Apple Therapeutics达成一项最高价值达8.12亿美元的合作协议，获取针对非促胰素类GPCR靶点的小分子药物。此次交易赋予诺和诺德在全球范围内获得Deep Apple小分子候选药物的许可权，这些药物面向一个尚未公开的、非促胰素GPCR靶点，具备治疗肥胖和其他心代谢疾病的潜力。为应对这一挑战，诺和诺德近年来加快了新项目的投资节奏。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4599":"减肥药","NVO":"诺和诺德","BK4144":"石油与天然气的储存和运输","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4007":"制药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","GLP":"Global Partners Lp","BK4588":"碎股","BK4590":"PTP","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4585":"ETF&股票定投概念","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC"},"translate_title":"Express | Over US $800 million deal reached! Novo Nordisk deploys non-GLP-1 weight loss drugs","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1,"GLP":1},"content_text":"整理 | GLP1减重宝典内容团队诺和诺德正进一步巩固其在快速增长的肥胖治疗市场中的领先地位，近日宣布与Deep Apple Therapeutics达成一项最高价值达8.12亿美元的合作协议，获取针对非促胰素类GPCR靶点的小分子药物。这一战略合作是该公司一系列研发投资中的最新动作，旨在锁定下一代代谢疾病疗法。Deep Apple Therapeutics由投资机构Apple Tree Partners发起成立，并获得了5200万美元的A轮融资。该公司结合人工智能与结构生物学技术，通过AI生成的虚拟化合物库及冷冻电镜手段，发现新型小分子候选药物。其平台可捕捉GPCR蛋白的动态构象变化，从而识别全新的结合位点。本次与诺和诺德合作的GPCR靶点不同于目前主流肥胖药物所靶向的促胰素类通路（如GLP-1和GIP）。此次交易赋予诺和诺德在全球范围内获得Deep Apple小分子候选药物的许可权，这些药物面向一个尚未公开的、非促胰素GPCR靶点，具备治疗肥胖和其他心代谢疾病的潜力。尽管具体靶点尚未披露，Deep Apple表示，其管线中有三个肥胖项目，其中两个不依赖GLP-1途径，显示出差异化的研发方向。根据协议，Deep Apple将负责候选化合物的发现和优化工作，诺和诺德则会参与早期研究计划，并在启动临床前IND研究之前接手全部开发工作。这一合作模式与诺和诺德近期的策略相一致：通过获取早期、机制差异化的资产，强化其长期创新能力。本次合作是在诺和诺德下一代肥胖候选药物CagriSema在三期临床试验中未达预期之后达成的。尽管该药显示出一定的减重效果，但结果未达到公司内部目标，令竞争对手礼来凭借替尔泊肽（tirzepatide）进一步稳固了在当前肥胖药物市场的领先地位。为应对这一挑战，诺和诺德近年来加快了新项目的投资节奏。公司近期已向Variant Bio提供5000万美元资金，与Valo Health达成1.9亿美元的合作扩展协议，还与Gensaic达成每个靶点高达3.54亿美元的交易，并投入2亿美元与United Laboratories合作开发三重激动剂。此外，还分别以2亿美元和7500万美元投资了Septerna和Lexicon Pharmaceuticals的临床前项目。诺和诺德与Deep Apple的合作，彰显了其向非促胰素机制、平台驱动型创新的战略转型。随着市场竞争加剧与行业发展提速，该公司正全力推动肥胖治疗的“下半场”，以机制多元化和前沿研发引领未来。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2543578562","isCrawlerRequest":true}